Business Wire

TYAN Introduces HPC, Cloud and Storage Server Platforms Featuring 4th Gen AMD EPYC™ Processors at SC22

15.11.2022 18:00:00 EET | Business Wire | Press release

Share

TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, brings the latest HPC, cloud and storage platforms powered by AMD EPYC™ 9004 Series processors for the next generation server architecture and energy efficiency at SC22, Booth #2000 in the Kay Bailey Hutchison Convention Center Dallas through November 17th.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005027/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TYAN Server Platforms Powered by AMD EPYC 9004 Series Processors are Designed for the Next Generation Server Architecture (Photo: Business Wire)

“Facing the post-COVID economy world, data centers are required to build on more environmentally friendly, secure and flexible features to respond to the growing of teleworking, video streaming, IoT and 5G,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation’s Server Infrastructure BU. “TYAN’s new server platforms, powered by 4th Gen AMD EPYC processors, efficiently enable data centers by doing more tasks with the same number of servers.”

"4th Gen AMD EPYC processors are the world's highest performance server CPUs that deliver leadership energy efficiency as well as low total cost of ownership across workloads and industries. By adopting 4th Gen AMD EPYC processors, enterprises can optimize their data center footprint to do more with less, accelerating their core business while helping address their sustainability goals," said Ram Peddibhotla, corporate vice president, EPYC product management, AMD.

Optimized for the most demanding workloads in today’s HPC data centers

Leveraging 4th Gen AMD EPYC processors’ support for high performance DDR5 memory and fast PCIe® Gen 5 I/O, TYAN’s HPC platforms enable the high performance demands of today’s AI and machine learning applications. The Tomcat HX S8050 server motherboard provides eight DDR5 DIMM slots, five PCIe 5.0 x16 slots, four MCIO connectors, two NVMe M.2 slots, two 10GbE and two GbE onboard Ethernet ports in CEB (12" x 10.5") form factor.

The Transport HX FT65T-B8050 is a rack-convertible pedestal server platform featuring a single AMD EYPC 9004 Series processor, eight DDR5 DIMM slots, eight 3.5” SATA and two 2.5” NVMe U.2 hot-swap, tool-less drive bays. The FT65T-B8050 supports up to two double-wide PCIe 5.0 x16 professional GPUs along with two additional high-speed networking adapters for parallel clustered workloads.

Data cache and high-density with front I/O servers to power the cloud

TYAN’s cloud platforms benefit from the innovations of AMD EPYC 9004 Series processors and are designed for cloud and data analytics applications that help move data faster. The Transport CX GC68A-B8056 is a cost-optimized single-socket server platform featuring 24 DDR5 DIMM slots, a pair of PCIe 5.0 x16 expansion slots, one OCP 3.0 LAN mezzanine slot and two 10GbE onboard Ethernet ports in 1U configuration. The GC68A-B8056 accommodates twelve 2.5” tool-less drive bays supporting NVMe U.2 devices for applications which require outstanding compute cores as well as high performance storage I/Os.

The Transport CX TD76-B8058 is a 2U multi-node server platform with four front-service nodes. Each node supports one AMD EPYC 9004 Series processor, 16 DDR5 DIMM slots, four hot-swap E1.S drive bays, two internal NVMe M.2 slots, one standard PCIe 5.0 x16 expansion, and one OCP 3.0 LAN mezzanine slot. The platform is suited for high-density data center deployment, front-end web servers, and variety of scale-out applications with large numbers of nodes.

Hybrid and all-flash storage server to maximize application performance

TYAN’s storage platforms are designed to deliver massive data I/O between memory and storage devices for cloud applications. TYAN's Transport SX TS70-B8056 and Transport SX TS70A-B8056 are 2U single-socket storage servers with support for 24 DDR5 DIMM slots, three PCIe 5.0 and one OCP 3.0 LAN mezzanine slots. The TS70-B8056 accommodates twelve front 3.5” drive bays with up to four NVMe U.2 support, and two rear 2.5” NVMe U.2 hot-swap, tool-less drive bays for boot drive deployment; the TS70A-B8056 offers 26 2.5” NVMe U.2 hot-swap, tool-less drive bays for high IOPs requirement in high-performance data streaming applications.

Supporting Resources:

Please watch this video about TYAN 4th Gen AMD EPYC processor-based servers designed for modern data centers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MiTAC Computing Technology Corporation/ Server Infrastructure Business Unit
Fenny Chen
fenny.chen@tyan.com.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye